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Interleukin-17A Facilitates
Chikungunya Virus Infection
by Inhibiting IFN-a2 Expression
Biswas Neupane, Dhiraj Acharya, Farzana Nazneen, Gabriel Gonzalez-Fernandez,
Alex Sutton Flynt and Fengwei Bai*
Department of Cell and Molecular Biology, Center for Molecular and Cellular Biosciences, The University of Southern
Mississippi, Hattiesburg, MS, United States
Interferons (IFNs) are the key components of innate immunity and are crucial for host
defense against viral infections. Here, we report a novel role of interleukin-17A (IL-17A) in
inhibiting IFN-a2 expression thus promoting chikungunya virus (CHIKV) infection. CHIKV
infected IL-17A deficient (Il17a−/−) mice expressed a higher level of IFN-a2 and developed
diminished viremia and milder footpad swelling in comparison to wild-type (WT) control
mice, which was also recapitulated in IL-17A receptor-deficient (Il17ra−/−) mice.
Interestingly, IL-17A selectively blocked IFN-a2 production during CHIKV, but not West
Nile virus (WNV) or Zika virus (ZIKV), infections. Recombinant IL-17A treatment inhibited
CHIKV-induced IFN-a2 expression and enhanced CHIKV replication in both human and
mouse cells. We further found that IL-17A inhibited IFN-a2 production by modulating the
expression of Interferon Regulatory Factor-5 (IRF-5), IRF-7, IFN-stimulated gene 49 (ISG-
49), and Mx1 expression during CHIKV infection. Neutralization of IL-17A in vitro leads to
the increase of the expression of these antiviral molecules and decrease of CHIKV
replication. Collectively, these results suggest a novel function of IL-17A in inhibiting
IFN-a2–mediated antiviral responses during CHIKV infection, which may have broad
implications in viral infections and other inflammatory diseases.
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INTRODUCTION
Chikungunya virus (CHIKV) is a reemerging mosquito-transmitted alphavirus of the Togaviridae
family that can cause crippling musculoskeletal inflammatory disease in humans that is
characterized by fever, polyarthralgia, myalgia, rash, and headache. CHIKV, first isolated in 1953
in Tanzania, was endemic in the tropic regions of Africa and the Indian Ocean (1). Due to the
increasing human travel and the rapid spread of the mosquito vectors to cooler climates, CHIKV
has dramatically expanded its territory and is currently circulating in over 60 countries, including
Africa, Asia, Europe, and the Americas (2). Since its introduction to the western hemisphere in
2013, CHIKV has caused an explosive epidemic in the Americas with over two million febrile cases
with debilitating polyarthralgia in about 50 countries (3). However, there are no specific treatments
or vaccines currently available, and the pathogenesis of CHIKV is largely unknown.
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CHIKV is primarily transmitted to humans by the bites of
infected female Aedes aegypti and Aedes albopictus mosquitos.
After mosquito inoculation, CHIKV replicates in human
epithelial cells, endothelial cells, and primary fibroblasts then
enters the lymph nodes and finally disseminate to other tissues
via the circulation (4, 5). Upon infection, the virus is sensed by
diverse innate immune pattern recognition receptors (PRRs),
such as toll-like receptors (TLRs), retinoic acid-inducible gene I
(RIG I), melanoma differentiation-associated gene 5 (MDA5),
and nod like receptors (NLRs). CHIKV infection induces the
production of proinflammatory cytokines, chemokines, and type
I interferons (IFN-a/b) (6). IFNa/b have been shown to play a
key role in limiting CHIKV replication in both humans and
mouse models (7). Fibroblasts are the primary target cells of
CHIKV infection and also are the major producers of CHIKV-
induced IFNa/b (8). Previous studies have revealed that the
CHIKV infection induces antiviral responses by activating
interferon regulatory factors (IRFs) (8, 9). IRF-5, along with
IRF-3 and IRF-7 induces the Interferon stimulated genes (ISGs)
during CHIKV infection (10). Further, IRF-7–mediated type I
IFN responses provide critical antiviral protection as neonatal
animals lacking either of these factors succumbed to CHIKV
infection (8). Interestingly, CHIKV was one of the virus models
used to discover and characterize the type I IFN (11–13).
However, the regulation of type I IFN production and
responses during CHIKV infection is still not clearly understood.
IL-17A, a best-characterized member of the IL-17 family, exerts
diverse immune functions, including host defense from infection,
tissue remodeling and repair, regulationof immune cell homing and
inflammation, and cancer progression (14). For example, a high
concentration of IL-17A in the joints contributes to inflammatory
arthritis and other allergic and autoimmune diseases (15–20). IL-
17A can facilitate WNV clearance frommouse brain by promoting
CD8+ T-cell cytotoxicity (21) and also inhibit the replication of
HSV by enhancing IFN-g+ Th1 cell response (22). IL-17A signaling
alsohasaprotective role to thehostduring infectionof adenovirusby
inducing high levels of IL-7R and RORgt expression in mouse liver
cells (23, 24). Similarly, IL-17A has also been suggested to facilitate
the infection of coxsackievirus B3 by decreasing splenic CD8+ T cell
numbers and cardiac IFN-g production (25) and Theiler’s murine
encephalomyelitis virus by up-regulating anti-apoptotic molecules
(26, 27). During CHIKV infection, the serum IL-17A levels in
patients with arthritis were higher than non-arthritic patients (28).
In addition, strong associations between IL-17A levels and swollen
joints have been identified (28, 29), suggesting IL-17Amight play an
important role in the pathogenesis of CHIKV; however, its detailed
role has not been characterized. In this study, we identified a novel
function of IL-17A signaling in promoting CHIKV infection by
negatively regulating IFN-a2–mediated antiviral responses.
MATERIALS AND METHODS
Ethics Statement and Biosafety
All the experimental procedures involving animals in this study
were reviewed and approved by the Institutional Animal Care
and Use Committees at The University of Southern Mississippi
(USM). Experiments and animal studies involving live CHIKV
were performed by certified personnel in Biosafety Level 3 (BSL-
3) laboratories following the biosafety protocols approved by the
USM Institutional Biosafety Committee.
Viruses
CHIKV (LR OPY1 2006 strain) was provided by University of
Texas Medical Branch. A single passage of parental viruses was
propagated in Vero cells (ATCC CCL-81) and used as viral stock
for this study. The viral stocks were titrated in Vero cells by
plaque assay as previously described (30, 31).
Cells
Vero cells, NIH3T3 cells (ATCC CRL-1658), and Raw 264.7 cells
(ATCC TIB-71) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM, Life Technologies) containing 1% L-glutamine,
1% penicillin/streptomycin, and 10% fetal bovine serum (FBS).
Saos2 cells (ATCCHTB-85) were cultured inMcCoy’s 5Amedium
(ATCC30-2007) supplementedwith15%FBS.All cellswere kept in
an incubator at 37°C with 5% CO2, and relative humidity of about
95%. Mouse BMDMs and BMDCs were prepared according to
previous publications (32–34).
Mice
WTC57BL/6J mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). Breeding pairs of Il17a−/− and Il17ra−/− mice
(both in a C57BL/6J background) were provided by Richard A.
Flavell (Yale University School of Medicine) and Dr. Sarah
Gaffen (University of Pittsburgh), respectively. All the breeders
and their pups were kept in a pathogen-free room. Viral infection
studies were carried out in the BSL-3 animal facility at USM.
Seven to eightweeksold, sex-matchedWT, Il17a−/−and Il17ra−/−
micewere subcutaneously injected on the ventral side of the left hind
footpad toward the ankle with 1 × 105 PFU of CHIKV in 50-µl
phosphate buffer saline (PBS), as mentioned in the previous
publications (33, 35). Starting from the day of infection (day 0) to
12days p.i., the thickness andwidthof the peri-metatarsal areaof the
infected feet were measured daily using a digital caliper (Electron
Microscopy Science). The relative increase in footpad swelling was
calculated and expressed in comparison to pre-infection as
previously described (33–36). Blood samples were collected in
0.5M EDTA by retro-orbital bleeding to analyze viral RNA and
cytokines. Mice were sacrificed at the selected time-points for
collection of the infected footpad.
Quantitative PCR
Total RNA was converted into the first-strand complementary
DNA (cDNA) using iSCRIPT™ cDNA synthesis kit (Bio-Rad).
QPCR assays were performed in a CFX Connect Real-Time
System (Bio-Rad) using SYBR Green supermix (Bio-Rad) for the
detection of CHIKV-E1, immune response genes, and b-actin.
Viral RNA copy numbers were expressed as the ratio of CHIKV-
E1 to cellular b-actin. For QPCR assay of immune response
genes, data were expressed as relative fold change (RFC)
expressed by DDCT method after normalizing to cellular b-
actin. CHIKV-E1 and cytokine transcripts were also quantified
by RT-QPCR in total RNA extracted from footpad cells. The
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primer sequences were designed using NCBI’s primer-designing
tool and synthesized by Integrated DNA Technologies or
Invitrogen (Supplementary Table 1).
Plaque Assay
Vero cells were plated in 6-welled plates at a density of 6 × 105
cells per well and incubated overnight. Cell culture supernatant
or mouse serum samples were applied to the wells and incubated
for 1 h at 37°C with 5% CO2. After virus adsorption, the
inoculum was removed, and the cells were covered with an
overlay medium containing 1% SeaPlaque agarose (Lonza). The
plates were incubated for 2 to 3 days for plaque development.
Plaques were visualized by staining with Neutral Red
and counted.
Flow Cytometry
For flow cytometric analysis of footpad immune cells, the
infected footpad tissues were collected to prepare single-cell
suspension as previously described protocol (37). Briefly, the
infected footpads were chopped into small pieces and incubated
for 1 h at 37°C in digestion medium containing hyaluronidase
and collagenase type VIII. The footpad cells were collected after
filtering the mixture with 70-µm strainer. The footpad cells were
fixed in 2% paraformaldehyde (Electron Microscopy Science) for
15 min at room temperature (RT). The cells were then washed
and blocked with Fc block for 30 min at RT. After washing, the
cells were probed with mouse monoclonal anti-CD45, CD4,
CD8, CD11b, and Ly6G antibodies (BD BioSciences or
eBioscience) and incubated for 1 h at RT. The cells were then
washed twice and resuspended in staining buffer and analyzed in
a BD LSRFortessa (BD Biosciences) using FlowJo (Version 10.4).
Histology
The infectedandcontrolmouse footpadswere collectedonday6p.i.
Afterfixation overnight in 4%PFA, the footpadswere decalcified in
10% EDTA for 10 days. Tissues were then dehydrated; paraffin
embedded, and sectioned (10 µm) using a microtome (American
Optical Spencer 820). The sectioned tissue slides were stained with
hematoxylin and eosin (H&E), and images were acquired using a
bright-field microscope (Olympus BH2).
ELISA and Immunoblotting
IL-17A and IFN-a2 in the cell culture supernatants of CHIKV-
infected NIH3T3 cells was measured by using a commercial
ELISA kit (Abcam) following the manufacturer’s instruction.
NIH3T3 cells were infected with CHIKV at 1 MOI in the
presence of recombinant IL-17A. After 24 h, the cells were
lysed in Laemmli sample buffer (Bio-Rad), and the proteins
were separated by 10% SDS-polyacrylamide gel electrophoresis,
transferred to a nitrocellulose membrane (Bio-Rad). The
membrane was blocked in 5% milk in Tris-buffered saline with
Tween 20 (TBS-T) for 1h at RT and probed with mouse specific
Rabbit primary antibody (Phospho-IRF-7, Cell Signaling;
Phospho-IRF-5, Invitrogen; GAPDH, Abcam) in the ratio
1:1,000 at 4°C overnight in a rocker. After washing with TBS-
T, horseradish peroxidase conjugated secondary antibody (Goat
pAb to Rabbit IgG, Abcam; 1:5,000) was added for 1 h at RT. The
membranes were washed and developed using SuperSignal West
Pico Chemiluminiscence Substrate (Thermo Scientific) and
images were acquired using a ChemiDoc MP system (Bio-
Rad). Quantification of blot was performed by ImageLab.
Statistical Analyses
Data analysis was performed by using either a Student’s t-test or
one-way analysis of variance (ANOVA) wherever applicable in
GraphPad Prism software (version 6.0). p < 0.05 was considered
statistically significant.
RESULTS
CHIKV Induces the Expression of
Il-17a In Vitro and In Vivo
IL-17A is a proinflammatory cytokine that plays essential roles in
infections and inflammatory diseases. To test our hypothesis if IL-
17Aplays a role inCHIKVpathogenesis, wemeasured its expression
in CHIKV-infected mouse and human cells. Mouse fibroblasts
(NIH3T3 cells) and human bone epithelial cells (Saos2 cells) were
infectedwithCHIKV(MOI0.1, 0.5, and1) for24h, and transcriptsof
Il-17a and cellularb-actin (a housekeeping gene)weremeasuredby a
reverse-transcription quantitative PCR (QPCR). The results showed
anupregulationof Il-17a transcriptsbyCHIKVinbothNIH3T3cells
(Figure 1A) and Saos2 cells (Figure 1B) in a dose-dependent
manner. To relate these results in a mouse model, we infected
C57BL/6J wild-type (WT) mice with CHIKV via footpad
inoculation, and the blood and footpad samples were collected on
days (D) 1 and 2 post-infection (p.i.). Similar to the in vitro results, Il-
17a transcript levels were significantly upregulated in the blood and
footpads of CHIKV-infected mice at D1 p.i. (Figures 1C, D). In
addition, ELISA results showed significant increases of IL-17A at
protein levels in theNIH3T3 cell culture (Figure 1E) and the plasma
samples on D1 p.i. (Figure 1F). These results demonstrate that
CHIKV infection induces the expressionof IL-17A inphysiologically
relevant human and mouse cells and mice.
IL-17A Promotes CHIKV-Induced
Footpad Swelling in Mice
To investigate the role of IL-17A in CHIKV-induced disease, we
infected 7 to 8 weeks old, sex-matched WT, IL-17A–deficient
(Il17a−/−), and IL-17A receptor-deficient (Il17ra−/−) mice with
1 × 105 PFU of CHIKV via footpad, as described in the previous
reports (32, 37). Following infection, the CHIKV inoculated
footpads usually swell between D1 and D12 p.i. in the adult
WT C57BL/6J mice (32, 38). We, therefore, monitored footpad
swelling daily for up to 12 days and calculated the relative
increase in footpad swelling of CHIKV-infected WT, Il17a−/−
and Il17ra−/− mice. The swelling data indicated that Il17a−/− and
Il17ra−/− mice had milder inflammation in their inoculated
footpads compared to WT control mice (Figure 2A). To
corroborate these observations, we collected blood on D1 and
2 p.i. and the viremia was measured by both QPCR and plaque
assay. The QPCR results showed a three-fold mean reduction of
CHIKVE1 transcripts on D1 p.i. in the Il17a−/− and Il17ra−/−
mice compared to WT mice (Figure 2B), whereas the CHIKV
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was mostly cleared from the blood on D2 p.i. Consistent with
QPCR, the plaque assay also showed less infectious viruses in
both Il17a−/− and Il17ra−/− mice (Figure 2C). After inoculation,
the CHIKV initially replicates locally in the footpad tissues.
Therefore, to assess whether the systemic viral replication is
similar to viral replication in the infected footpad, we sacrificed
selected mice and collected the tissues of the infected footpad on
D1 and 2 p.i. and performed the QPCR analysis. Consistent with
the viremia, there was an approximately two-fold reduction in
CHIKVE1 RNA in the foot tissues of Il17a−/− and Il17ra−/− mice
compared to the WT controls on D1 (Figure 2D). Despite the
differences are not statistically significant, a similar trend
remains on D2 p.i. (Figure 2D).
To further dissect this observation, we performed histological
and flow cytometric analysis with the inoculated footpad tissues at
peak swelling (D6 p.i.). The histological analysis showed that the
peri-metatarsal area of the inoculated footpads of Il17a−/− and
Il17ra−/−mice had less severe swelling and tissue damage compared
to that of WT mice (Figure 2E). In addition, the flow cytometric
analysis demonstrated a significantly reduced infiltration of
neutrophils (CD45+CD11b+Ly6G+) in the footpad of Il17ra−/−
mice compared to WT mice (p < 0.05), while the differences are
not statistically significant (p > 0.05) for other immune cells
including CD4 T cells (CD45+CD3+CD4+), CD8 T cells
(CD45+CD3+CD8+), and monocytes (CD45+CD11b+) (Figure
2F). A similar trend, but with no statistical difference, of these
infiltrated cells was also observed in Il17a−/−mice compared toWT
mice (data not shown). Together, these results suggest that IL-17A
signaling facilitates CHIKV replication and exacerbates CHIKV-
induced footpad inflammation in mice.
IL-17A Inhibits the Ifn-a2 Expression
to Promote CHIKV Replication
Asweobserved that thedeficiency in IL-17Asignaling inmice led to
a significantly reducedCHIKV replication in the blood and footpad
tissues, we hypothesized that IL-17A signaling may inhibit the
antiviral innate immune responses. To test this, we profiled the
expression of a set of innate antiviral genes in CHIKV-infectedWT
and Il17ra−/− mice by QPCR analysis. Interestingly, we found that
among 11 different genes tested (Ifn-a, Ifn-b, Ifn-g, Rig-I, Mda-5,
Myd88, Tlr3, Tlr9, Il-12, Cxcl2, and Cxcr3), the expression of Ifn-a
was significantly increased in the blood of Il17ra−/− mice (Figure
3A). There are multiple Ifn-a subtypes in mice, and we further
tested the effect of IL-17A signaling in the expression of these
subtypes upon CHIKV infection. Interestingly, of the 11 Ifn-a
subtypes tested, specifically the expression of Ifn-a2 transcripts was
significantly inhibited in CHIKV-infected NIH3T3 cells
(Supplementary Figure 1). To further validate these results, we
first confirmedthat theexpressionof Ifn-a2was inducedbyCHIKV
inNIH3T3, Saos2 cells, andmice (Figures 3B–D).Wenext tested if
the expression of CHIKV-induced Ifn-a2 inNIH3T3 cells could be
inhibited by recombinant mouse IL-17A (rIL-17A). Both QPCR
and ELISA results indicated that rIL-17A treatment suppressed the




FIGURE 1 | CHIKV infection induces the expression of Il17a in mouse and human. (A, B) The expression of Il17a transcripts was measured by QPCR in NIH3T3
(A) and Saos2 (B) cells that were infected with indicated MOIs of CHIKV for 24 h and expressed as Relative Fold Changes (RFC) after normalization to cellular
b-actin transcripts. WT (C57BL/6J) mice (7 to 8 weeks old) were inoculated with CHIKV (1 × 105 PFU) or vehicle control (PBS) via footpad, and blood was collected
on days (D) 1 and 2 post-infection (p.i.). (C, D) RFC in the expression of Il17a transcripts in blood (C) and footpad (D) of CHIKV-infected mice was compared with
that of mock-infected control mice after normalization to b-actin. (E, F) The protein levels of IL-17A was measured by ELISA in NIH3T3 cells (E) and mice blood (F).
The results were analyzed either by using one-way ANOVA followed by Tukey’s test (A, B, E) or a two-tailed student’s t-test (C, D, F). The results are representative
of at least two independent experiments and are expressed as mean ± the standard errors of the mean (SEM) [n = 3 biological replicates for (A, B, E); n = 7 to 11
mice/group for (C, D, F). *, **, ***, and **** denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively.
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cells. Consistently, this phenotype was also confirmed in other cell
types, i.e., Raw 264.7 cells, mouse bone marrow–derived
macrophages (BMDM), and bone marrow–derived dendritic cells
(BMDCs) (Figures 3G–L), suggesting a cell type-independent effect.
We next measured the expression levels of Ifn-a2 in Il17a−/− and
Il17ra−/−mice that lack IL-17A signaling to further determine if IL-
17A signaling inhibits the expression of Ifn-a2 in vivo following
CHIKV infection. Indeed, the mRNA level of Ifn-a2 in blood and
footpads was increased in both Il17a−/− and Il17ra−/− mice than in
WTmice, confirming the inhibitory effect of IL-17A on theCHIKV-
induced expression of Ifn-a2 (Figures 3M–P).
To test if IL-17A also inhibits the expression of Ifn-a2 during
other virus infections, we infected NIH3T3 cells with West Nile
virus (WNV) or Zika virus (ZIKV) in the presence of rIL-17A,
and measured Ifn-a2 mRNA by QPCR or ELISA. Interestingly,
the results suggested that IL-17A has no such effect on IFN-a2
production during WNV and ZIKV infections (Supplementary
Figures 2A–C). IL-17F, a closely related member of IL-17 family,
has related functions to IL-17A and also shares the same set of
receptors IL-17RA and IL-17RC. To test if IL-17F function
similarly with IL-17A in the regulation of IFN-a2, we





FIGURE 2 | Il17a−/− and Il17ra−/− mice are more resistant to CHIKV infection. Seven to eight weeks old WT, Il17a−/− and Il17ra−/− mice were infected with 1 × 105
PFU of CHIKV via footpad. (A) Swelling of injected footpads (peri-metatarsal area) of mice is presented as a relative increase in swelling that was calculated by
measuring the thickness and width of an inoculated footpad. (B) Blood was collected on days 1 (D1) and D2 p.i., and QPCR was performed to measure the copies
of CHIKV E1 and cellular b-actin transcripts. Viral burden was expressed as a ratio of copy number of CHIKV E1 to cellular b-actin transcripts and compared
between WT (n = 22) and Il17a−/− (n = 17) or Il17ra−/− (n = 16) mice. (C) Plaque assay was performed to measure the viral load in the blood samples of D1 from (B).
(D) Inoculated footpads of WT (n = 14) and Il17a−/− (n = 9) or Il17ra−/− (n = 9) were collected on D1 and D2 p.i., and the viral burden was quantified by QPCR after
normalization to cellular b-actin. (E) Representative H&E stained histological images (10×, upper row and 20×, lower row) of peri-metatarsal area of the inoculated
foot tissue (n = 5 mice/group) on D6 p.i. The layer of epidermis (a) and dermis (b) are labeled. (F) Seven to 8 weeks old WT (n = 4) and Il17ra−/− mice (n = 3) were
infected with 1 × 105 PFU of CHIKV via footpad. Footpad cells were isolated at D6 p.i., and quantified by flow cytometry after probing with antibodies against CD45,
CD4, CD8, CD11b, and Ly6G. The cell counts for positive cells within the gated population are shown for WT and Il17ra−/− mice. The results are expressed as mean
± SEM (A–D, F) or a representative image (E) that represents at least three independent experiments. The data were analyzed by a two-tailed Student t-test
(A–D, F). *, **, and **** denote p < 0.05, p < 0.01, and p < 0.0001 respectively, when compared to WT controls).
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FIGURE 3 | IL-17A down-regulates the expression of Ifn-a2. (A) Seven to eight weeks old WT (n = 5) and Il17ra−/− mice (n = 6) were infected with 1 × 105 PFU of
CHIKV via footpad and the transcripts of indicated genes in blood were measured at day 1 post-infection by QPCR and normalized to b-actin mRNA. (B) NIH3T3
and (C) Saos2 cells were infected with CHIKV for 24 h, and the transcript level of Ifn-a2 was measured by QPCR and normalized to b-actin mRNA. (D) Seven to
eight weeks old WT mice were mock infected (n = 7) or infected with 1 × 105 PFU of CHIKV (n = 6) via footpad and the expression of Ifn-a2 was measured by
QPCR in the blood at indicated time points and normalized to b-actin mRNA. (E) NIH3T3 cells were infected with CHIKV (MOI = 1) and treated with indicated
concentrations of rIL-17A for 24 and 48 h. The expression of Ifn-a2 was measured by QPCR and normalized to cellular b-actin mRNA. (F) The protein level of IFN-
a2 was measured by ELISA in NIH3T3 cells infected with CHIKV (MOI = 1) and treated with different concentrations of rIL-17A. (G, H) Raw 264.7 cells were infected
with CHIKV (MOI = 1) in the presence of indicated concentrations of rIL-17A and incubated for 24 and 48 h followed by the measurement of mRNA level (G) and
protein level (H) of IFN-a2. (I–L) Mouse bone marrow derived-macrophages (I, J) and dendritic cells (K, L) were infected with CHIKV (MOI = 1) for 48 h in the
presence of rIL-17A (100 ng/ml). The level of Ifn-a2 was measured either by QPCR normalized to cellular b-actin mRNA or by ELISA. (M, N) WT (n = 4), Il17a−/−
(n = 8) and Il17ra−/− mice (n = 10) were infected with 1 × 105 PFU of CHIKV via footpad. Blood was collected on days 1 and 2 post-infection, and the mRNA level of
Ifn-a2 was measured by QPCR and normalized to b-actin mRNA between WT and Il17a−/− mice (M), and WT and Il17ra−/− mice (N). Ifn-a2 mRNA levels in the
footpads of Il17a−/− mice (O) and Il17ra−/− mice (P) were measured by QPCR and normalized to b-actin mRNA. All the data represent at least two independent
experiments performed in triplicates and analyzed by one-way ANOVA followed by Turkey’s test, (*, **, and *** denote p < 0.05, p < 0.01, and p < 0.001
respectively, when compared to untreated control).
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NIH3T3 cells upon recombinant IL-17F (rIL-17F) treatment
(Supplementary Figures 2D, E). Our results demonstrated
that only IL-17A, but not IL-17F, inhibited the CHIKV-
induced IFN-a2 expression. As a consequence, the treatment
of rIL-17A after CHIKV infection significantly increases the
virus replication in NIH3T3 cells (Figures 4A, B), which may
be due to the reduced antiviral IFN-a2 production. In another
experiment, we also tested if the cells pretreated with rIL-17A
could enhance susceptibility to CHIKV infection. The results
showed that the pretreatment with rIL-17A, but not rIL-17F,
enhanced CHIKV replication (Figures 4C, D), implying that IL-
17A constrains the production of IFN-a2 thus facilitating
CHIKV replication. The antiviral activities of IFN-a2 were
confirmed by the experiment showing that the presence of
rIFN-a2 constrains CHIKV replication in NIH3T3 cells
(Figures 4E, F), while the addition of rIL-17A neutralizes the
antiviral effects of rIFN-a2 (Figure 4G). However, it does not
rule out that the observed effect of IL-17A happens
independently of CHIKV infection. Next, we tested if the
presence of IL-17A neutralizing antibody could inhibit the
effects of CHIKV-induced IL-17A. We infected NIH3T3 cells
with CHIKV in the presence of IL-17A neutralizing antibody or
anti-flavivirus 4G2 antibody as an isotype control. The results
show that CHIKV replication is inhibited and the expression
level of Ifn-a2 increases in the presence of IL-17A neutralizing
antibody, but not of the control antibody (Figures 4H, I).
Collectively, these results demonstrate that IL-17A signaling
inhibits the production of IFN-a2, thus facilitating the CHIKV
replication in vitro and mice.
IL-17A Inhibits the Expression of
Ifn-a2 via IRF-5 and 7 Pathways
We next hypothesized that IL-17A signaling interrupts the
signaling pathway(s) that differentially regulate the expression
of Ifn-a subtypes and thus inhibiting the expression of Ifn-a2.
Relative amounts of IRF genes have been shown to modulate the
differential expression of various IFN-A subtypes during





FIGURE 4 | IL-17A, but not IL-17F, promotes CHIKV replication in NIH3T3 cells. (A, B) NIH3T3 cells were infected with CHIKV (MOI =1) in the presence of indicated
concentrations of rIL-17A for 48 h. The ratio of CHIKVE1 to cellular b-actin transcripts was determined by QPCR (A) and the number of infectious virus in the culture
supernatants were measured by a plaque assay (B). (C) NIH3T3 cells were preincubated for 24 h with indicated concentrations of rIL-17A, then infected with CHIKV
(MOI = 1) for an additional 48 h. The ratio of CHIKVE1 RNA to cellular b-actin transcripts was determined by QPCR. (D) NIH3T3 cells were infected with CHIKV (MOI
= 1) in the presence of IL-17F for 48 h, and the ratio of CHIKVE1 RNA to cellular b-actin transcripts was determined by QPCR. (E, F) NIH3T3 cells were treated with
recombinant IFNA2 for 8 h and then infected with CHIKV at 1 MOI for 24 h. The ratio of CHIKVE1 to cellular b-actin transcripts was determined by QPCR (E) and the
infectious virus in the cell medium were measured by a plaque assay (F). (G) NIH3T3 cells were treated with rIL-17A and IFNA2, then infected with CHIKV at 1 MOI
for 24 h. The ratio of CHIKVE1 to cellular b-actin transcripts was measured by QPCR. (H, I) NIH3T3 cells were infected with CHIKV (1 MOI) in the presence of rIL-
17A, IL-17A neutralizing antibody or anti-flavivirus 4G2 antibody as an isotype control for 24 h. The ratio of CHIKVE1 to cellular b-actin mRNA was determined by
QPCR (H) and the expression of Ifn-a2 was measured by QPCR and normalized to cellular b-actin mRNA (I). All the data represent at least two independent
experiments performed in triplicates and analyzed by one-way ANOVA followed by Turkey’s test, (*, **, and *** denote p < 0.05, p < 0.01, and p < 0.001,
respectively, when compared to untreated control). ns denotes not significant.
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play protective roles against CHIKV infection (9). Therefore, we
assessed the role of IL-17A signaling in the expression of IRF
genes during CHIKV infection. We infected NIH3T3 cells with
CHIKV in the presence of rIL-17A for QPCR analysis, and the
results showed that the expression of Irf-3, Irf-5, and Irf-7 was
inhibited at the transcriptional levels (Figures 5A–C). In
addition, the immunoblotting analysis suggests that IL-17A
inhibits the phosphorylation IRF-5 and IRF-7 during CHIKV
infection (Figures 5D, E), while the phosphorylation of IRF-3
was not detected (data not shown). Considering IL-17A inhibits
the expression and phosphorylation of IRF-5 and IRF-7 in the
cell culture during CHIKV infection, we measured the levels of
Irf-5 and Irf-7 mRNA in mice blood and footpads following
CHIKV infection. Consistent with the results, the levels of Irf-5 are
significantly upregulated in the blood and footpads of Il17a−/− and
Il17ra−/− mice compared to WT control mice (Figures 5F–H). A
similar trend is also shown for Irf-7, although the difference is not
statistically significant (Figures 5I–K). These results indicate that
IL-17A may inhibit the expression of Ifn-a2 via IRF-5 and 7
pathways. We next tested if IL-17A signaling inhibits IFN-
mediated antiviral responses. We tested the expression of a set of
ISGs (Isg-15, Isg-49, Isg-54, Isg-56,Oas1a,Mx1, Ifitm3, and bst2) by
QPCR in the blood and footpads ofWT, Il17a−/− and Il17ra−/−mice
following CHIKV infection. Interestingly, we found that among
those test ISGs, Isg-49, and Mx1 were significantly upregulated in
Il17a−/− and Il17ra−/−mice footpads compared to theWT controls
(Figures 5L–M). Similar patterns were observed in the blood,
although the difference was not significant (data not are shown).
We further confirmed that the expression of Irf-5, Irf-7, Isg-49, and
Mx1 were upregulated in the presence of IL-17A neutralizing
antibody in CHIKV-infected NIH3T3 cells (Figures 5N–Q).
Collectively, these results demonstrate that IL-17A signaling
inhibits IFN-a2–mediated antiviral responses during
CHIKV infection.
DISCUSSION
IL-17A signaling has been associated with several inflammatory
diseases in humans, such as rheumatoid arthritis (40, 41), systemic
lupus erythematosus (42), and Crohn’s disease (43, 44). Among its
diverse functions, IL-17A can regulate the activities of various other
inflammatory cytokines, which include TNF-a, IL-1b, and IFN-g
(45–48). For example, IL-17A signaling has also been shown to
upregulate joint destructive factors by stimulating transcriptional
NF-kB activity and expression of IL-1, granulocyte/macrophage
colony-stimulating factor (GM-CSF), prostaglandin E2, IL-6, IL-8,
and TNF-a in fibroblasts, endothelial and epithelial cells, and
inducing T cell proliferation (46, 49–56). In this study, we report
a novel role of IL-17A in inhibiting IFN-a2 expression during
CHIKV infection.
CHIKV infection in humans can induce severe inflammatory
responses and chronic arthritis, which is correlated with the
increased production of IL-17A in patients (6, 57). As such, it is
plausible to hypothesize that IL-17A may play an important role
in the pathogenesis of CHIKV. We detected a significant up-
regulation of Il-17a in both human and mouse cells, and mouse
blood and footpads following CHIKV infection (Figure 1).
Interestingly, the CHIKV burden was negatively regulated by
IL-17A signaling as both Il17a−/− and Il17ra−/− mice exhibited
lower CHIKV loads in their blood and mild swelling in
inoculated footpads compared to those of WT mice (Figure 2).
These results suggest that IL-17A signaling facilitates CHIKV
replication and disease in mice. In mouse models, after
subcutaneous inoculation of CHIKV via footpad, biphasic
swelling responses usually occur in the inoculated footpad.
Two peaks of swelling can be observed on around days 1–3
and 5–7 p.i., respectively. Mice also develop severe arthritis,
tendonitis, and fasciitis in the inoculated foot, but these
inflammatory effects are generally milder in the contralateral
foot without swelling (32, 34, 38). Consistent with these results,
in our study, the major peak of CHIKV-induced footpad
swelling occurred on day 6 p.i. when the viruses had been
cleared from the animal circulation, which suggests that the
second peak of the swelling is largely mediated by pathogenic
immune responses.
Type I IFN signaling has been shown to play an essential role
in controlling infections of alphaviruses including CHIKV (58–
60). Inhibition of type I IFN signaling in mice causes severe
CHIKV-associated disease due to higher viral loads and virus
dissemination to the CNS (58, 61). As the major target cells,
fibroblasts can be infected by CHIKV in vitro and in vivo (4, 7)
and are the major source of type I IFNs responding to CHIKV
infection (7). Our results on NIH3T3 cells indicate that IL-17A
inhibits IFN-a2 expression during CHIKV infection
(Supplementary Figure 1 and Figure 3). We also showed the
same effect of IL-17A on the other cell types, such as BMDMs
and dendritic cells, as well as mouse macrophage cells (Raw
264.7), suggesting that IL-17A inhibits IFN-a2 expression during
CHIKV infection in a cell-type independent manner. The
blockade of IFN-a in mice results in the increases of CHIKV
viral loads in the infected foot and serum demonstrating its
importance in restricting viral replication and spread (62). Our
in vitro results show that CHIKV replication is supported by IL-
17A, which may be due to the decrease in the production of IFN-
a2. We further showed that Ifn-a2 was upregulated in Il17a−/−
and Il17ra−/−mice compared toWTmice after CHIKV infection,
which may be the reason for lowering the level of CHIKV after
infection. Our results further suggest that IL-17A, but not IL-
17F, specifically inhibits the expression of IFN-a2 during
CHIKV, but not WNV or ZIKV infection (Figure 4 and
Supplementary Figure 2). Both IL-17A and IL-17F belong to
the same cytokine family and bind to the same receptors, but
their specificity and binding affinity to the receptors differ. This
might account for the differences observed in the inhibition of
IFN-a2 and the replication of CHIKV in the presence of IL-17A
and IL-17F. Alphaviruses are known for their antiviral counter
defense strategies during infection, the C-terminal domain of
CHIKV nsP2 specifically inhibits IFN response by promoting the
nuclear export of STAT1 (63). Further, alphaviruses have
evolved mechanisms to obstruct antiviral responses by
inhibiting specific signaling pathways and modulating the host
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cell shutoff by the inhibition of general transcription and/or
translation (64, 65). These properties of CHIKV might be
involved in the inhibition of IFN-a2 expression during CHIKV
infection, but not during WNV and ZIKV infection.
In mice, the family of type I IFN consists of 14 IFN-a
subtypes and single forms of IFN-b, IFN-ϵ, IFN-k, and IFN-w
(66). In response to viral infection, host cell PRRs recognize the








FIGURE 5 | IL-17A downregulates the expression of Irf5 and Irf7 during CHIKV infection. NIH3T3 cells were infected with CHIKV (MOI = 1) and simultaneously
treated with indicated concentrations of rIL-17A for 48 h. The transcripts of Irf-3 (A), Irf-5 (B), and Irf-7 (C) were measured by QPCR and expressed as RFC after
normalization to cellular b-actin mRNA. (D) NIH3T3 cells were infected with CHIKV (MOI = 1) for 24 h in the presence of IL-17A (100 ng/ml) and indicated proteins in
the cell lysates were analyzed by immunoblotting (left) and the ratio of phosphorylated IRF-5 to GAPDH was calculated by densitometric measurement by using
ImageLab (right). (E) The immunoblotting analysis was done similarly for IRF-7 and GAPDH (left), and the ratio of phosphorylated IRF-7 to GAPDH was calculated by
densitometric measurement by using ImageLab (right). (F, G) WT (n = 4), Il17a−/− (n = 10), and Il17ra−/− (n = 10) mice were infected with 1 × 105 PFU of CHIKV via
footpad. Blood was collected on days 1 and 2 post-infection, and the mRNA levels of Irf-5 were measured and normalized to b-actin mRNA between WT and
Il17a−/− mice (F), and WT and Il17ra−/− mice (G). Footpads were collected from selected WT (n = 4) and Il17a−/− (n = 4) mice on D1 p.i., and the mRNA level of Irf-5
was measured and normalized to b-actin mRNA between WT and Il17a−/− mice (H). The mRNA levels of Irf-7 were measured in the blood of Il17a−/− mice (I), the
blood of Il17ra−/− mice (J), and the footpads of Il17a−/− mice (K). (L, M) Isg-49 and Mx1 mRNAs in the footpads (n = 5 to 10/group) on D1 p.i. (N–Q) NIH3T3 cells
were infected with CHIKV (1 MOI) in the presence of IL-17A, anti-Il17A antibody or 4G2 control antibody for 24 h. The level of Irf-5 (N), Irf-7 (O), Isg-49 (P), and Mx1
(Q) were measured and normalized to cellular b-actin mRNA. The data (A–C and N–Q) represent the results of two independent experiments carried out in
triplicates, and analyzed by one-way ANOVA followed by Turkey’s test, (*, **, and *** denote p < 0.05, p < 0.01, and p < 0.001 respectively, when compared to
untreated control). The results (F–M) represent three independent experiments analyzed by a two-tailed Student t-test, (*, **, and *** denote p < 0.05, p < 0.01, and
p < 0.001 respectively, when compared to WT controls). ns denotes not significant.
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through activation of IRF-3 (67–71). Through autocrine and
paracrine signaling, these IFNs modulate the expression of
various transcriptional factors and ultimately induce expression
of diverse IFN subtypes and IFN stimulated genes (ISGs). One of
the transcriptional regulators induced by these IFNs is IRF-7,
which induces all other IFN-a subtypes in a positive feedback
loop, thus amplifying the response (72–74). Thus, IRF-3, IRF-5,
and IRF-7 are considered to be the master regulators of type I
IFN induction and ISG expression. The combined effect of these
three transcription factors has been shown to coordinately
regulate IFN response during WNV infection (75). In lethal
CHIKV infection, the survival time of Irf3−/− Irf7−/− double
knockout mice are longer than Ifnar1−/− mice (7), thus
speculating the role of additional transcription factors, such as
IRF-5, contributing to the IFN response after CHIKV infection.
Here, we show that IRF-3, IRF-5, and IRF-7 are inhibited by IL-
17A at the mRNA levels during CHIKV infection; however, the
phosphorylation of IRF-3 was not detectable by immunoblotting,
suggesting IRF-3 may not play an essential role mediating IL-
17A–IFN-a2 pathway. Instead, the expression and
phosphorylation of Irf-5 and Irf-7 are inhibited by IL-17A,
indicating that IL-17A signaling inhibits IFN-a2 mainly by
affecting IRF-5 and IRF-7 mediated pathways (Figure 5). Type
I IFNs bind to their receptors and initiate the JAK-STAT
signaling pathways and induce the production of the ISGs that
are critical to control viral replication. Our results show the
transcript levels of Isg-49 and Mx1 decrease in the presence of
rIL-17A while increase in the presence of IL-17A neutralizing
antibody during CHIKV infection, thus suggesting IL-17A
directly or indirectly inhibits the ISG-49 and Mx1-mediated
antiviral responses against CHIKV replication.
Different IFN types may exert different functions during
CHIKV infection, IFN-a limits early viral replication and
dissemination; while IFN-b modulates neutrophil-mediated
inflammation (62). Among IFN-a subtypes, IFN-a2 can be
induced by Herpes Simplex Virus, Respiratory Syncytial Virus,
and Newcastle Disease Virus (76). It has antiviral effects against
influenza A virus and human metapneumovirus (76–78). We
found that IL-17A inhibits the expression of IFN-a2 during
CHIKV infection in a variety of cell types. The level of IFN-a2
was decreased and the viral replication was increased during
CHIKV infection in the presence of rIL-17A. Our results also
indicate only IFN-a2, but not the other 10 tested IFN-a subtypes
is inhibited by IL-17A. Therefore, these results suggest that the
increase of the production of IFN-a2 in the absence of IL-17A
signaling may contribute to the reduced viral burden in the blood
and footpad during CHIKV infection. Supporting this
hypothesis, we showed that the level of CHIKV is less in the
infected cells in the presence of recombinant IFNA2. Consistent
with the previous research that has demonstrated that type I IFN
signaling is essential to mitigate CHIKV-induced pathogenicity
in mice (9, 62). Furthermore, we found that the infiltration of
neutrophils into the footpads of Il17ra−/− mice was significantly
reduced compared to WT mice on day 6 p.i. when the second
peak of footpad swelling occurred. Neutrophils have been shown
to be a major player contributing to CHIKV-induced
inflammation and tissue damage in joints (79), which may be
due to the increased level of inflammatory mediators, such as
CXCL1, CXCL2, granulocyte colony-stimulating factor (G-CSF),
IL-1b , and decreasing the level of anti-inflammatory
macrophages. The lower viral burdens in the early phase of
CHIKV infection seen in Il17a−/− and Il17ra−/− mice, may cause
reduced levels of these inflammatory mediators, thus leading to a
less severe footpad swelling on day 6 p.i.
In conclusion, our study discovers a novel role of IL-17A in
inhibiting IFN-a2 production during CHIKV infection. Further
studies are warranted to dissect the mechanism by which IL-17A
regulates CHIKV-induced IFN-a2 expression, which may have
broad implications in the understanding of IL-17A regulated
immunity and development of novel IL-17A–based
therapeutic strategy.
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